Source 1review2023Signal Transduction and Targeted Therapy
Toolkit/CAR-T
CAR-T
Also known as: CAR T cells, CAR-T cells, chimeric antigen receptor (CAR) T cells
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
The web research summary identifies CAR-T as explicitly supported by the anchor review figures/text and by multiple discovered reviews centered on synthetic-biology engineering of CAR-T cells.
Usefulness & Problems
Why this is useful
CAR-T is presented as a T cell-based immunotherapy modality that has shown notable success in hematological malignancies and is being developed for solid tumors.; T cell-based immunotherapy; CAR-T refers to T cells engineered with chimeric antigen receptors for targeted immune activity. The abstract describes CAR-T as a major CAR modality used in cancer and increasingly in autoimmune disease.; treatment of hematologic and solid tumours; autoimmune disease applications; CAR-T is presented as a major engineered-cell therapeutic modality within the review's synthetic biology scope.; engineered cell therapy; synthetic-biology-based immunotherapy
Source:
CAR-T is presented as a T cell-based immunotherapy modality that has shown notable success in hematological malignancies and is being developed for solid tumors.
Source:
T cell-based immunotherapy
Source:
CAR-T refers to T cells engineered with chimeric antigen receptors for targeted immune activity. The abstract describes CAR-T as a major CAR modality used in cancer and increasingly in autoimmune disease.
Source:
treatment of hematologic and solid tumours
Source:
autoimmune disease applications
Source:
CAR-T is presented as a major engineered-cell therapeutic modality within the review's synthetic biology scope.
Source:
engineered cell therapy
Source:
synthetic-biology-based immunotherapy
Problem solved
It aims to use engineered T cells to attack cancer, extending adoptive cell therapy into solid tumors.; Provides an engineered T cell modality for cancer treatment; It provides targeted, programmable immune intervention for malignancy and some non-malignant diseases.; targeted immune-cell therapy for cancer and non-malignant disease; It offers a programmable cell-based therapeutic approach in immunotherapy.; providing an engineered cellular therapeutic modality
Source:
It aims to use engineered T cells to attack cancer, extending adoptive cell therapy into solid tumors.
Source:
Provides an engineered T cell modality for cancer treatment
Source:
It provides targeted, programmable immune intervention for malignancy and some non-malignant diseases.
Source:
targeted immune-cell therapy for cancer and non-malignant disease
Source:
It offers a programmable cell-based therapeutic approach in immunotherapy.
Source:
providing an engineered cellular therapeutic modality
Problem links
Provides an engineered T cell modality for cancer treatment
LiteratureIt aims to use engineered T cells to attack cancer, extending adoptive cell therapy into solid tumors.
Source:
It aims to use engineered T cells to attack cancer, extending adoptive cell therapy into solid tumors.
providing an engineered cellular therapeutic modality
LiteratureIt offers a programmable cell-based therapeutic approach in immunotherapy.
Source:
It offers a programmable cell-based therapeutic approach in immunotherapy.
targeted immune-cell therapy for cancer and non-malignant disease
LiteratureIt provides targeted, programmable immune intervention for malignancy and some non-malignant diseases.
Source:
It provides targeted, programmable immune intervention for malignancy and some non-malignant diseases.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
Computational DesignTarget processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: actuator
Requires overcoming solid-tumor barriers including heterogeneity, suppressive TME, infiltration, and persistence; The abstract highlights manufacturing as a key aspect, indicating engineered T-cell production is required.; requires engineered T-cell manufacturing; It requires engineered T-cell generation and therapeutic cell-manufacturing workflows, though the payload does not provide protocol detail.; requires engineered T-cell manufacturing context
The abstract states that CAR-T efficacy in solid tumors remains limited by antigen heterogeneity, suppressive TME, and poor infiltration and persistence.; Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment; Affected by insufficient T cell infiltration and persistence; Can face antigen escape; Can cause on-target off-tumor toxicity; The abstract notes persistent issues including antigen escape, cost, manufacturing complexity, and solid-tumour microenvironment barriers.; antigen escape; manufacturing complexity; high costs; tumour microenvironment challenges; The available evidence does not specify how the review treats toxicity, persistence, antigen escape, or manufacturing bottlenecks.; the available payload does not provide specific design constraints, safety issues, or efficacy boundaries
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2primary paper2026MED
Source 3primary paper2026MED
Ranked Claims
Antigen escape, on-target off-tumor toxicity, and suppressive tumor microenvironment features are important biological and technical challenges that impede treatment efficacy in solid-tumor T cell immunotherapy.
Particular attention is given to the biological and technical challenges that impede treatment efficacy, including antigen escape, on-target off-tumor toxicity, and the suppressive features of the TME.
CAR-NK approaches are being used to target HIV.
CAR-NK approaches targeting HIV
CAR-Tregs enhance transplant tolerance.
CAR-Tregs enhancing transplant tolerance
CD19/BCMA-targeted CAR-T cells have achieved long-term remission in lupus and rheumatoid arthritis without ongoing immunosuppression.
CD19/BCMA-targeted CAR-T cells achieving long-term remission in lupus and rheumatoid arthritis without ongoing immunosuppression
Senolytic CARs reduce tissue fibrosis.
senolytic CARs reducing tissue fibrosis
CAR-T cells have achieved notable success in hematological malignancies.
T cell-based immunotherapies have achieved notable success in the treatment of hematological malignancies, particularly through the application of chimeric antigen receptor (CAR) T cells.
Logic-gated CARs are highlighted as an innovation in next-generation CAR therapy design.
Innovations like off-the-shelf allogeneic products and logic-gated CARS are highlighted
Off-the-shelf allogeneic CAR products are highlighted as an innovation in CAR-engineered therapies.
Innovations like off-the-shelf allogeneic products and logic-gated CARS are highlighted
The clinical efficacy of T cell-based immunotherapies in solid tumors remains limited by tumor antigen heterogeneity, immunosuppressive tumor microenvironment, and insufficient T cell infiltration and persistence.
However, the clinical efficacy of such approaches in solid tumors remains limited due to a range of intrinsic and extrinsic barriers, including tumor antigen heterogeneity, the immunosuppressive tumor microenvironment (TME), and insufficient T cell infiltration and persistence.
The CAR-engineered therapy landscape includes CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells
Significant advances have been made in the development of CAR-T, TCR-T, and TIL therapies for solid tumors.
Despite these challenges, significant advances have been made in recent years in the development of CAR-T cells, T cell receptor-engineered T cells (TCR-T), and tumor-infiltrating lymphocytes (TILs) for solid tumors.
The review discusses Tet-on/Tet-off systems and optogenetic circuits as controllable expression or control modalities in tissue-engineering and mammalian-system contexts.
Tet-on/Tet-off system ... explicitly discussed in the anchor review's tissue-engineering section as a controllable expression system. Optogenetic circuits ... explicitly discussed in the anchor review's tissue-engineering section and supported by its mammalian control-system discussion.
The review includes engineered-cell therapeutic themes involving CAR-T and synNotch-associated cell-circuit design.
CAR-T ... explicitly supported by the anchor review figures/text ... synNotch ... explicitly mentioned in the anchor review's CAR design figure/text.
This review covers synthetic biology applications in medical and pharmaceutical fields including microbial pharmaceutics production, engineered cells with synthetic DNA circuits, live or auto-assembled biomaterials, cell-free synthetic biology, and DNA engineering approaches.
Anchor review confirmed in PubMed; abstract explicitly states the major subtopics covered: microbial pharmaceutics production, engineered cells with synthetic DNA circuits, live/auto-assembled biomaterials, cell-free synthetic biology, and DNA engineering approaches.
Approval Evidence
3 sources7 linked approval claimsfirst-pass slug car-t
including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells
Source:
T cell-based immunotherapies have achieved notable success in the treatment of hematological malignancies, particularly through the application of chimeric antigen receptor (CAR) T cells.
Source:
The web research summary identifies CAR-T as explicitly supported by the anchor review figures/text and by multiple discovered reviews centered on synthetic-biology engineering of CAR-T cells.
Source:
challengesupports
Antigen escape, on-target off-tumor toxicity, and suppressive tumor microenvironment features are important biological and technical challenges that impede treatment efficacy in solid-tumor T cell immunotherapy.
Particular attention is given to the biological and technical challenges that impede treatment efficacy, including antigen escape, on-target off-tumor toxicity, and the suppressive features of the TME.
Source:
clinical applicationsupports
CD19/BCMA-targeted CAR-T cells have achieved long-term remission in lupus and rheumatoid arthritis without ongoing immunosuppression.
CD19/BCMA-targeted CAR-T cells achieving long-term remission in lupus and rheumatoid arthritis without ongoing immunosuppression
Source:
efficacy contextsupports
CAR-T cells have achieved notable success in hematological malignancies.
T cell-based immunotherapies have achieved notable success in the treatment of hematological malignancies, particularly through the application of chimeric antigen receptor (CAR) T cells.
Source:
limitationsupports
The clinical efficacy of T cell-based immunotherapies in solid tumors remains limited by tumor antigen heterogeneity, immunosuppressive tumor microenvironment, and insufficient T cell infiltration and persistence.
However, the clinical efficacy of such approaches in solid tumors remains limited due to a range of intrinsic and extrinsic barriers, including tumor antigen heterogeneity, the immunosuppressive tumor microenvironment (TME), and insufficient T cell infiltration and persistence.
Source:
modality diversificationsupports
The CAR-engineered therapy landscape includes CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells
Source:
progresssupports
Significant advances have been made in the development of CAR-T, TCR-T, and TIL therapies for solid tumors.
Despite these challenges, significant advances have been made in recent years in the development of CAR-T cells, T cell receptor-engineered T cells (TCR-T), and tumor-infiltrating lymphocytes (TILs) for solid tumors.
Source:
application themesupports
The review includes engineered-cell therapeutic themes involving CAR-T and synNotch-associated cell-circuit design.
CAR-T ... explicitly supported by the anchor review figures/text ... synNotch ... explicitly mentioned in the anchor review's CAR design figure/text.
Source:
Comparisons
Source-stated alternatives
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.; Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.; The payload points to broader engineered cell therapeutics and synNotch-linked circuit designs as nearby approaches.
Source:
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Source:
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The payload points to broader engineered cell therapeutics and synNotch-linked circuit designs as nearby approaches.
Source-backed strengths
Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section
Source:
Notable success in hematological malignancies
Source:
clinical expansion beyond oncology is reported
Source:
highlighted as a focused therapeutic modality within the review's engineered-cell section
Compared with CAR-engineered macrophages
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Compared with CAR-macrophages
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Compared with CAR-MΦ
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Compared with CAR-NK
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Compared with CAR-NKT cells
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Compared with CAR-T cells
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Compared with CAR-T therapy
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Compared with chimeric antigen receptor macrophage
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Compared with chimeric antigen receptor macrophages
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Compared with chimeric antigen receptor natural killer cells
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Compared with chimeric antigen receptor T cells
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Compared with Chimeric antigen receptor T-cell therapy
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Compared with HER2-targeting CAR-M
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
Other CAR-engineered cell modalities named in the abstract include CAR-NK, CAR-macrophages, and CAR-NKT cells.
Compared with TCR-T
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Notable success in hematological malignancies; clinical expansion beyond oncology is reported; highlighted as a focused therapeutic modality within the review's engineered-cell section.
Relative tradeoffs: Clinical efficacy in solid tumors remains limited; Affected by tumor antigen heterogeneity; Affected by immunosuppressive tumor microenvironment.
Source:
The review contrasts CAR-T with TCR-T and TIL-based therapies, and discusses combination strategies such as checkpoint blockade, combinatorial antigen targeting, synthetic biology, and gene editing.
Ranked Citations
- 1.
- 2.
- 3.